← ANALYST RATINGS · TIPRANKS
Meiragtx Holdings (MGTX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $25.00, the highest $30.00, the lowest $20.00. The average is +169.4% from the last price of $9.28.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $10.00−9.1% | Hold | +7.8% | Downgrade | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $10.00−9.1% | Buy | +7.8% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $10.00−4.8% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.00 → $9.50−5.0% | Hold | +2.4% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $10.50−8.7% | Buy | +13.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.00−9.1% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $16.00 | Hold | +72.4% | Initiated | 24.09.26on TipRanks Sep 25 02:35 | −5.9%next day −1.8% · 5 days −3.1% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $30.00 | Buy | +223.3% | Reiterated | 17.08.26on TipRanks 07:38 | +2.3%next day +1.5% · 5 days +8.9% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $19.00 | Buy | +104.7% | Reiterated | 14.08.26on TipRanks 07:10 | +6.9%next day +2.3% · 5 days +7.4% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $20.00 | Buy | +115.5% | Reiterated | 14.08.26on TipRanks Aug 13 13:35 | −2.9%next day +6.9% · 5 days +16.7% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $26.00 → $27.00+3.8% | Buy | +190.9% | Reiterated | 13.08.26on TipRanks Aug 14 08:35 | −2.9%next day +6.9% · 5 days +16.7% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $20.00 | Buy | +115.5% | Reiterated | 09.07.26on TipRanks 09:12 | −2.3%next day −4.4% · 5 days −11.4% | ↗ |
| Unknown Analyst | Raymond James | — | Buy | — | Reiterated | 24.06.26on TipRanks Jun 26 21:02 | −1.7%next day −0.7% · 5 days +8.6% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $35.00 | Buy | +277.2% | Reiterated | 14.05.26on TipRanks 18:10 | −4.3%next day +0.1% · 5 days −2.6% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $20.00 → $18.00−10.0% | Buy | +94.0% | Reiterated | 01.04.26on TipRanks 08:05 | +4.2%next day +0.9% · 5 days −1.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Meiragtx Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.00 at a price of $11.00 (+100.0%); now: $22.40 at $9.28 (+141.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 2 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.50 (from $-0.63 to $-0.37). Last quarter: $1.71.
Sales
Next quarter’s sales estimate — $7M (from $2M to $18M). Last quarter: $321M.
Best top-analyst consensus in the sector · Healthcare
About Meiragtx Holdings
- CEO: Alexandria Forbes
- Employees: 393
- 655 Third Avenue, New York City, NY, 10017, US
- www.meiragtx.com
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Data from the stock’s TipRanks forecast page, read 165 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗